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Calcitonin gene-related peptide-evoked sustained tachycardia in
calcitonin receptor-like receptor transgenic mice is mediated by
sympathetic activity
Abstract
Calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) are potent vasodilators and exert
positive chronotropic and inotropic effects on the heart. Receptors for CGRP and AM are calcitonin
receptor-like receptor (CLR)/receptor-activity-modifying protein (RAMP) 1 and CLR/RAMP2
heterodimers, respectively. The present study was designed to delineate distinct cardiovascular effects of
CGRP and AM. Thus a V5-tagged rat CLR was expressed in transgenic mice in the vascular
musculature, a recognized target of CGRP. Interestingly, basal arterial pressure and heart rate were
indistinguishable in transgenic mice and in control littermates. Moreover, intravenous injection of 2
nmol/kg CGRP, unlike 2 nmol/kg AM, decreased arterial pressure equally by 18 +/- 5 mmHg in
transgenic and control animals. But the concomitant increase in heart rate evoked by CGRP was 3.7
times higher in transgenic mice than in control animals. The effects of CGRP in transgenic and control
mice, different from a decrease in arterial pressure in response to 20 nmol/kg AM, were suppressed by 2
micromol/kg of the CGRP antagonist CGRP(8-37). Propranolol, in contrast to hexamethonium, blocked
the CGRP-evoked increase in heart rate in both transgenic and control animals. This was consistent with
the immunohistochemical localization of the V5-tagged CLR in the superior cervical ganglion of
transgenic mice. In conclusion, hypotension evoked by CGRP in transgenic and control mice was
comparable and CGRP was more potent than AM. Unexpectedly, the CLR/RAMP CGRP receptor
overexpressed in postganglionic sympathetic neurons of transgenic mice enhanced the positive
chronotropic action of systemic CGRP.
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First published July 27, 2007; doi:10.1152/ajpheart.00629.2007.—Calci-
tonin gene-related peptide (CGRP) and adrenomedullin (AM) are potent
vasodilators and exert positive chronotropic and inotropic effects on the
heart. Receptors for CGRP and AM are calcitonin receptor-like recep-
tor (CLR)/receptor-activity-modifying protein (RAMP) 1 and CLR/
RAMP2 heterodimers, respectively. The present study was designed
to delineate distinct cardiovascular effects of CGRP and AM. Thus a
V5-tagged rat CLR was expressed in transgenic mice in the vascular
musculature, a recognized target of CGRP. Interestingly, basal arterial
pressure and heart rate were indistinguishable in transgenic mice and
in control littermates. Moreover, intravenous injection of 2 nmol/kg
CGRP, unlike 2 nmol/kg AM, decreased arterial pressure equally by
18  5 mmHg in transgenic and control animals. But the concomitant
increase in heart rate evoked by CGRP was 3.7 times higher in
transgenic mice than in control animals. The effects of CGRP in trans-
genic and control mice, different from a decrease in arterial pressure in
response to 20 nmol/kg AM, were suppressed by 2mol/kg of the CGRP
antagonist CGRP(8-37). Propranolol, in contrast to hexamethonium,
blocked the CGRP-evoked increase in heart rate in both transgenic and
control animals. This was consistent with the immunohistochemical
localization of the V5-tagged CLR in the superior cervical ganglion of
transgenic mice. In conclusion, hypotension evoked by CGRP in trans-
genic and control mice was comparable and CGRP was more potent than
AM. Unexpectedly, the CLR/RAMP CGRP receptor overexpressed in
postganglionic sympathetic neurons of transgenic mice enhanced the
positive chronotropic action of systemic CGRP.
calcitonin gene-related peptide; sympathetic nervous system; baro-
receptor reflex
- AND -CALCITONIN GENE-RELATED PEPTIDE (CGRP) are 37 amino
acid neuropeptides derived from separate genes. -CGRP is
widely distributed in the central and peripheral nervous system,
whereas -CGRP is primarily located in enteric nerves and in
the pituitary gland (1). -CGRP and -CGRP belong to the
calcitonin (CT) family of peptides, which includes ad-
renomedullin (AM) and amylin (16). CGRP and AM are potent
vasodilators (2) and exert positive chronotropic and inotropic
effects on the heart. Distinct actions of CGRP and AM on the
cardiovascular system remain to be delineated. This has been
addressed in the present study in transgenic mice expressing a
V5-tagged rat CT receptor-like receptor (CLR) under control
of a smooth muscle -actin promoter, e.g., in the vascular
musculature.
CGRP immunoreactive nerve fibers terminate in blood ves-
sels, primarily small arteries. They are found at the junction of
the adventitia and the media and extend into the muscle layer
(11). These observations are consistent with the reported va-
sodilatory activity of CGRP. In the heart of several mammals,
including man, CGRP innervates the atria and, to a limited
extent, the ventricles (6, 12, 14). In the atria, CGRP-containing
nerve fibres are found in the sino-atrial node, the atrio-ventric-
ular node, and the conduction system. Systemic administration
of CGRP in humans and rats has direct positive chronotropic
action not blocked by labetalol (4, 9). Studies on the inotropic
action of CGRP on the heart revealed conflicting results (1). In
humans, labetalol suppressed the inotropic action of CGRP,
indicating that it is secondary to reflex activation of the
sympathetic nervous system (9). In the isolated perfused heart
of guinea pigs, CGRP provoked increased contractile force not
affected by the -adrenoceptor antagonist metoprolol (7).
Cardiovascular effects of AM have been studied in con-
scious sheep and rabbits (8, 17). AM, much like CGRP,
provoked decreased blood pressure concomitant with increased
heart rate and cardiac output. In a recent study in sheep, AM
increased the cardiac sympathetic nerve activity (3). In the
isolated rat heart, AM had a positive inotropic effect without
affecting the heart rate (19).
Both CGRP and AM interact with the CLR that forms
heterodimers with single transmembrane-domain receptor-
activity-modifying proteins (RAMP). The three so far identi-
fied are RAMP1, -2, and -3, and they determine the ligand
selectivity of the CLR (15). CGRP predominantly interacts
with CLR/RAMP1, whereas AM is recognized when the CLR
is associated with RAMP2 or -3. Thus the responsiveness of a
given tissue to AM and/or CGRP depends on the levels of
expression of the CLR and the corresponding RAMP.
In the present study, the effects of systemically administered
CGRP and AM on arterial blood pressure and heart rate were
investigated in transgenic mice expressing a V5-tagged rat
CLR (V5-CLR) under the control of a smooth muscle -actin
promoter in the vascular musculature. Littermates were used as
control animals. Basal arterial pressure, heart rate, and the
vasodilatory response to CGRP and AM were indistinguishable
in V5-CLR transgenic and control mice. However, transgenic
animals exhibited sustained tachycardia in response to CGRP
but not to equal amounts of AM. The effects of CGRP were
suppressed by the CGRP(8-37) antagonist and by the -
adrenergic receptor-blocking agent propranolol but not by the
ganglion-blocker hexamethonium. Thus CGRP likely increases
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the heart rate in transgenic mice through interaction with CLR/
RAMP1 CGRP receptors localized on postganglionic sympathetic
neurons and independent of the baroreceptor reflex.
MATERIALS AND METHODS
Chemicals. Rat -CGRP, -CGRP(8-37), and AM were purchased
from Bachem (Bubendorf, Switzerland). All the peptides were dis-
solved in isotonic saline (0.9% NaCl) immediately before use. Pro-
pranolol was from AstraZeneca (Inderal, 1 mg/ml lyophilized to 10
mg/ml) and hexamethonium from Sigma (Buchs, Switzerland, dis-
solved in isotonic saline to obtain 25 mg/ml).
Generation and characterization of CLR transgenic mice. Four
independent CLR founders were obtained by pronuclear injection of a
transgene encoding the V5-CLR (Fig. 1A) into B6D2F1  B6D2F1
oocytes (10). Founders and offspring were genotyped by PCR analysis
of genomic DNA extracted from tail biopsies with transgene specific
forward (5-GGCCCTGGCCATGGAAGAAGG-3) and reverse (5-
TGGGACCATGGATGATGTAGAGG-3) primers. PCR products
with a predicted size of 880 bp were identified with agarose gel electro-
phoresis (Fig. 1B). Expression of the V5-CLR in smooth muscle con-
taining tissues was verified by Western blot analysis of extracts of
indicated tissues with antibodies to V5 (Invitrogen, Carlsbad, CA) and
with monoclonal smooth muscle -actin specific antibodies (Sigma) and
secondary alkaline phosphatase-conjugated antibodies (Jackson Immmu-
noResearch Laboratories, West Grove, PA) (Fig. 1C).
Surgery and experimental procedure. All animal experiments con-
formed to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publication No.
85–23, Revised 1996), and institutional guidelines and were approved
by the Kantonales Veterina¨ramt Zu¨rich.
Four- to five-month-old CLR transgenic mice and control litter-
mates were investigated. Anesthesia was induced with a mixture of
4% halothane, 70% N2O, and 26% O2 and maintained by reducing the
inhaled halothane concentration to 1–1.5%. Body temperature was
maintained at 37°C using a temperature-controlled heating pad. Cath-
eters were inserted into the left femoral artery and vein for the analysis
of pH, PCO2, PO2, and base excess (pHOx-Plus, Nova Biomedical,
Waltham, MA) and for the recording of arterial blood pressure. The
arterial catheter was connected to a piezo-electric pressure transducer
connected to a bio-potential amplifier (Hugo Sachs Electronics, March,
Germany), and the pressure signal was used to calculate the heart rate
from peak to peak with a heart rate module (Hugo Sachs Electronics).
The signals from the bio-potential amplifier and the heart rate module
were digitized, recorded, and analyzed offline with the Power-Lab system
(ADInstruments, Spechbach, Germany). After completion of surgery, the
anesthesia was changed to intravenous ethomidate at an infusion rate of
7–10 l/min, and 30 min later indicated amounts of peptides were
administrated as 50-l iv bolus injections of corresponding stock solu-
tions. Cardiovascular parameters were monitored for 1 h after the injec-
tion of the reagents or until they returned to basal values. Changes in heart
rate have been analyzed as area under the curve during the 5 min after the
injection of the peptides. The maximal decrease in the arterial blood
pressure was also evaluated.
One group of experimental animals was treated with a continuous
infusion of propranolol (2 mg kg1 min1) or hexamethonium
(5 mg kg1 min1) commencing 30 min before the injection of pep-
tides.
Collection of sympathetic ganglia. CLR transgenic mice and con-
trol littermates were transcardially perfused with ice-cooled 0.1 M
phosphate buffer (PB; pH 7.4), and fixed with 4% paraformaldehyde
in PB. The superior cervical ganglion was removed with the carotid
bifurcation and immersed in 4% paraformaldehyde in PB for 2 h,
cryoprotected in 20% sucrose in PB for 24 h at 4°C, and frozen at
20°C. Serial 10-m sections of tissue specimens were obtained with
a cryostat, mounted on Superfrost plus slides (Menzel-Glaser, Ger-
many), and kept at 20°C until use.
Immunohistochemistry. Superior cervical ganglion sections were
pretreated with 0.3% H2O2, washed in PBS, and incubated for 2 h in
1.5% rabbit normal serum or 1.5% goat serum diluted in PBS
containing 0.3% Triton X-100. The sections were then incubated with
antibodies to tyrosine hydroxylase (Novus Biologicals, Littleton, CO;
1:10,000, 48 h) or to the V5 epitope-tag (Bethyl Laboratories, Mont-
gomery, TX; 1:10,000, 1 h). Subsequently, the sections were incu-
bated with biotinylated goat anti-rabbit or rabbit anti-goat IgG (1:200,
2 h) and further processed using the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA), according to the instructions of the
manufacturer. The bound antibodies were visualized with 3,-3 dia-
minobenzidine-tetrahydrochloride (Sigma) as a chromogene. The sec-
tions were washed in PBS containing 0.3% Triton X-100 (10 min, 3
times) between incubations.
Statistics. Data are presented as means  SE and analyzed with the
GraphPad PRISM 4 Software (version 4.01) using ANOVA and
Students t-test for unpaired samples with Bonferroni correction.
P values of 0.05 were considered significant.
RESULTS
Basal blood parameters. pH, PCO2, PO2, base excess, and
hematocrit measured in arterial blood before the administration
of drugs and peptides did not differ between control and
transgenic mice (Table 1).
Cardiovascular effects of CGRP. Arterial blood pressure and
heart rate were continuously recorded in anesthetized CLR
transgenic mice and control littermates before and after intra-
venous injection of 2 nmol/kg CGRP. Basal arterial blood
pressure and heart rate in CLR transgenic mice were 79  2
Fig. 1. Generation of V5 rat calcitonin receptor-like receptor (CLR) transgenic
mice. A: the transgene consists of a smooth muscle -actin promoter, a DNA
fragment encoding the signal sequence of the CD33 protein (CD33), a V5
epitope-tag (V5), the cDNA of the rat CLR, and the polyadenylation signal of
the bovine growth hormone gene [A(n)]. Arrows labeled P1 and P2 indicate the
position of forward and reverse primers used for genotyping the mice.
B: agarose gel electrophoresis of PCR-amplified DNA from mouse tail biop-
sies with the predicted 880-bp transgene-derived product (arrowhead) present
in CLR transgenic (CLRSMA) mice but not in control (wt) littermates.
C: expression of the V5-CLR (V5) and smooth muscle -actin (SMA) in
indicated tissues of wt and CLRSMA mice revealed by Western blot analysis.
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mmHg and 361  26 beats/min, respectively, and indistin-
guishable from 78  5 mmHg and 369  29 beats/min in
control animals. Intravenous injection of 2 nmol/kg CGRP in
CLR transgenic mice and control animals resulted in a com-
parable transient decrease in arterial blood pressure that re-
turned to basal levels within 6 min of peptide administration
(Fig. 2). However, the concomitant increased heart rate, esti-
mated as area under the curve during the 5 min after injection
of CGRP, was 3.7 times higher in CLR transgenic mice than in
control animals. Moreover, in CLR transgenic mice, the heart
rate remained elevated at 140  8% of basal values at least 30
min after the administration of CGRP. This sustained elevation
was not observed in control littermates.
Intravenous injection of 2 mol/kg of the CGRP(8-37)
antagonist had no effect on systemic blood pressure in trans-
genic and control mice. However, it suppressed the decrease in
arterial blood pressure in response to CGRP to a similar extent
in control and CLR transgenic animals (Fig. 2). The CGRP
evoked increase in heart rate in CLR transgenic mice was also
lowered by CGRP(8-37) to values comparable to those of
control mice. The CGRP antagonist did not affect the moderate
CGRP-induced increase in heart rate observed in control mice.
The evidence for CGRP-specific effects on arterial pressure in
control and transgenic animals and on the heart rate in CLR
transgenic mice was supported by additional observations.
Administration of up to 10 times higher amounts of salmon CT
than of CGRP did not affect arterial blood pressure or heart rate
in CLR transgenic mice and control littermates (not shown).
Moreover, 10 times higher amounts of AM than of CGRP were
required to obtain a modest decrease in arterial blood pressure
in control (not shown) and transgenic mice that was not
blocked by CGRP(8-37). Taken together, the results indicate
that the higher and prolonged elevation of the heart rate in CLR
transgenic mice in response to systemically administered
CGRP is mediated by the CLR/RAMP1 CGRP receptor. The
sustained CGRP evoked increase in heart rate is unlikely to
result from the transient decrease in arterial blood pressure.
Effect of propranolol and hexamethonium on the action of
CGRP. The enhanced chronotropic action of CGRP was fur-
ther investigated in CLR transgenic mice and control litter-
mates receiving a constant infusion of the -adrenergic recep-
tor blocking agent propranolol or the ganglionic blocker hexa-
methonium (Fig. 3). Treatment of control and CLR transgenic
mice with propranolol lowered the arterial blood pressure to
40–50 mmHg. Intravenous injection of 2 nmol/kg CGRP in
propranolol-treated mice led to a further transient drop in
arterial blood pressure indistinguishable in control and CLR
Table 1. Basal blood parameters in control
and transgenic mice
pH PCO2, Torr PO2, Torr Base Excess, mM Hematocrit, %
wt 7.30.1 42.05.4 11626 2.55.5 43.33.8
tg 7.30.1 38.74.9 11632 2.15.8 41.03.7
Values are means  SD. wt, Control mice; tg, calcitonin receptor-like
receptor transgenic mice.
Fig. 2. Effect of intravenously administered calcitonin
gene-related peptide (CGRP) alone, or CGRP(8-37) and
CGRP, or AM in sequence on heart rate and arterial
blood pressure. Representative tracings of heart rate and
arterial blood pressure (top). Bottom left: mean changes
in heart rate and blood pressure in control (wt; open
bars) and CLR transgenic (tg; shaded bars) mice in
response to intravenous injection of 2 nmol/kg CGRP.
The maximal drop in arterial blood pressure was similar
in wt and tg mice. The heart rate, estimated as area
under the curve (AUC) during the 5 min after intrave-
nous injection of CGRP, increased to higher levels in tg
than in wt mice. Bottom right: changes in heart rate and
arterial blood pressure in wt and tg mice in response to
2 nmol/kg CGRP or 20 nmol/kg AM in the presence of
2 mol/kg CGRP(8-37) antagonist. The decrease in
arterial blood pressure and the increase in heart rate
evoked by CGRP were suppressed by CGRP(8-37). In
contrast, CGRP(8-37) did not affect the AM-evoked
drop in arterial blood pressure. Values are means  SE;
n 	 5. *P  0.05 vs. the response to CGRP in wt and
tg mice in the presence of CGRP(8-37).
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transgenic mice and similar to that seen in the absence of
propranolol. Importantly, the CGRP evoked increase in heart
rate observed in untreated control and CLR transgenic mice
was blocked by propranolol. These findings are consistent with
activation of the sympathetic nervous system in CLR trans-
genic mice by intravenous CGRP rather than by a direct action
of CGRP on the heart. Our finding that hexamethonium had no
effect on the CGRP-evoked heart rate response in CLR trans-
genic mice supports this interpretation and points to a direct
action of CGRP on postganglionic neurons.
Immunohistochemistry. Sympathetic ganglia have been
identified through staining with antibodies to tyrosine hydrox-
ylase (Fig. 4). V5 staining in sections from CLR transgenic
mice localized the CLR to cell bodies. Interestingly, nerve
fibers did not stain with antibodies to the V5-CLR.
DISCUSSION
The present study introduces transgenic mice that express
the rat CLR under the control of a smooth muscle -actin
promoter in vascular tissue and, unexpectedly, also in the
superior cervical ganglion. The transgenic mice responded to
intravenously injected CGRP with an increased heart rate of
higher amplitude and longer duration than control littermates.
Interestingly, hypotension provoked by intravenous CGRP was
indistinguishable in CLR transgenic and control mice. Appar-
ently, expression of the transgenic rat CLR in the vascular
smooth muscle cell layer, a known target of CGRP, did not
increase the sensitivity to CGRP or AM. Counterregulation
of increased CGRP or AM sensitivity in vascular smooth
muscle cells as a result of downregulation of CGRP or AM
receptor signaling in CLR transgenic mice or inadequate
expression of RAMP1 or -2 cannot be ruled out. The
CGRP(8-37) antagonist was ineffective when administered
alone. But the hypotensive effect of CGRP was suppressed
in both transgenic and control mice by CGRP(8-37). Impor-
tantly, the antagonist lowered the increased positive chro-
notropic action in transgenic animals. In contrast, equal
amounts of AM were ineffective in all mice. Thus the
observed chronotropic and hypotensive effects in transgenic
and wild-type animals are specific for CGRP. Altogether,
the results indicate a predominantly baroreflex-independent
positive chronotropic action of intravenously administered
CGRP in CLR transgenic mice. This is in line with obser-
vations in the rat where over 10-fold higher doses of CGRP
Fig. 3. Effect of propranolol and hexamethonium treat-
ment on the CGRP-evoked changes in heart rate and
arterial blood pressure. Top left: representative tracings
of heart rate and arterial blood pressure before and after
intravenously injected CGRP (2 nmol/kg) in wt and tg
mice treated with propranolol (2 mg  kg1  min1).
Basal arterial blood pressure in wt and tg mice was
lower than in untreated mice (see Fig. 2, top left).
Bottom left: CGRP injection during propranolol infu-
sion resulted in comparable arterial blood pressure de-
creases in tg and wt mice. However, the effect on heart
rate, estimated as AUC of recordings during the 5 min
after intravenous injection of CGRP, was abolished,
suggesting a CGRP-dependent mechanism upstream of
the sino-atrial node independent of the parasympathetic
nervous system. Top right: representative tracings of
heart rate and arterial blood pressure before and after
intravenous injection of CGRP (2 nmol/kg) in wt and tg
mice infused with hexamethonium (5 mg  kg1  min1).
Bottom right: during hexamethonium treatment, the
effect of CGRP on heart rate and arterial blood pressure
was indistinguishable from that seen in untreated ani-
mals (see Fig. 2, left). This suggests that CGRP exerts
its effect on postganglionic neurons. Values are
means  SE; n 	 5. *P  0.05 vs. controls.
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than those used here provoked long-lasting tachycardia in
the face of a transiently decreased arterial pressure (5).
The long-lasting increased heart rate in CLR transgenic mice
may be mediated by a direct action of CGRP on the sino-atrial
node or by modulation of the activity of the sympathetic
nervous system. To test these hypotheses, we treated the mice
with propranolol or hexamethonium. The CGRP-evoked tachy-
cardia was blocked by propranolol, indicating CGRP signaling
upstream of the sino-atrial node. In contrast, hexamethonium
did not affect the CGRP-evoked increased heart rate. These
findings, together with the immunohistochemical localization
of the V5-CLR in the superior cervical ganglion, point to the
expression of CGRP receptors in postganglionic neurons of
transgenic mice and imply unexpected and, as of yet, unex-
plained activity of the otherwise smooth muscle tissue-specific
-actin promoter.
Endogenous CGRP receptors have been localized in sympa-
thetic ganglia (13, 20). Moreover, Seyedi et al. (18) demon-
strated a CGRP-provoked release of norepinephrine from iso-
lated sympathetic nerves of the guinea pig heart. In the dog,
positive inotropic action of intravenous CGRP was attributed
to sympathetic activation brought about through interaction of
CGRP with receptors in stellate ganglia (13). This effect was
blocked by the -adrenergic blocking agent timolol but not by
the ganglionic blocking agent hexamethonium. These findings,
much like those of the present study, indicate direct actions of
CGRP on the heart mediated through the sympathetic nervous
system.
In conclusion, intravenous CGRP provoked tachycardia of
higher amplitude and longer duration in CLR transgenic mice
compared with nontransgenic littermates. This effect was
blocked by propranolol but not by hexamethonium, suggesting
a baroreceptor reflex-independent positive chronotropic action
of CGRP on the heart of CLR transgenic mice. The effects are
mediated by CLR/RAMP1 CGRP receptors expressed on post-
ganglionic sympathetic neurons. This is in accordance with
the observed expression of the transgene-derived CLR in the
superior cervical ganglion. These findings together with the
previously reported inotropic action of CGRP in the dog
indicate that CGRP modulates the cardiac output in part
through stimulation of myocardial sympathetic activity. The
activation of the sympathetic nervous system is a defensive
mechanism inhibiting the impact of vasodilation and hypoten-
sion.
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